Centre for Atherothrombosis and Metabolic Disease, Hull York Medical School, University of Hull, Hull HU6 7RX, UK.
School of Chemistry and Bioscience, University of Bradford, Bradford BD7 1DP, UK.
Pharmacol Res. 2021 Mar;165:105467. doi: 10.1016/j.phrs.2021.105467. Epub 2021 Jan 27.
Cardiovascular diseases (CVDs) are the leading cause of death globally. While the major focus of pharmacological and non-pharmacological interventions has been on targeting disease pathophysiology and limiting predisposing factors, our understanding of the cellular and molecular mechanisms underlying the pathogenesis of CVDs remains incomplete. One mechanism that has recently emerged is protein O-GlcNAcylation. This is a dynamic, site-specific reversible post-translational modification of serine and threonine residues on target proteins and is controlled by two enzymes: O-linked β-N-acetylglucosamine transferase (OGT) and O-linked β-N-acetylglucosaminidase (OGA). Protein O-GlcNAcylation alters the cellular functions of these target proteins which play vital roles in pathways that modulate vascular homeostasis and cardiac function. Through this review, we aim to give insights on the role of protein O-GlcNAcylation in cardiovascular diseases and identify potential therapeutic targets in this pathway for development of more effective medicines to improve patient outcomes.
心血管疾病（CVDs）是全球范围内的主要死因。虽然药理学和非药理学干预的主要重点一直是针对疾病的病理生理学和限制诱发因素，但我们对 CVDs 发病机制的细胞和分子机制的理解仍然不完整。最近出现的一种机制是蛋白质 O-GlcNAcylation。这是一种动态的、特异性的、可逆的翻译后修饰丝氨酸和苏氨酸残基的靶蛋白，由两种酶控制：O-连接的β-N-乙酰葡萄糖胺转移酶（OGT）和 O-连接的β-N-乙酰氨基葡萄糖苷酶（OGA）。蛋白质 O-GlcNAcylation 改变了这些靶蛋白的细胞功能，这些靶蛋白在调节血管稳态和心脏功能的途径中发挥着至关重要的作用。通过这篇综述，我们旨在深入了解蛋白质 O-GlcNAcylation 在心血管疾病中的作用，并确定该途径中的潜在治疗靶点，以开发更有效的药物来改善患者的预后。
